Company intelligence / Profile preview

Koanaa Healthcare

Fischamend-Dorf, Lower Austria, Austria

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Koanaa Healthcare is commercializing at least one already FDA-approved small molecule oncology drug (imatinib mesylate) with strong published efficacy and safety results in chronic myeloid leukemia and other indications. Their clinical activities appear to focus on originator/legacy small molecule oncology therapeutics.[9]

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Teva Pharmaceuticals Europe BV

Beyond the preview

Go deeper on Koanaa Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Koanaa Healthcare.

Explore the full profile